Eurobio Scientific launches its COVID antigen self-test

Eurobio Scientific launches its COVID antigen self-test

Paris, June 2, 2021 – 5:45 pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in specialty in vitro medical diagnostics, announces the launch of its new proprietary test EBS 1005, an antigen self-test developed to identify the presence of the SARS-CoV-2 coronavirus by simple nasal sampling.

An easy to use proprietary antigen self-test

The proprietary EBS 1005 test received today an exemption from the French health authority, ANSM, to be marketed until CE marking is obtained. It also received a similar waiver from German health authorities. The test is intended to be sold in boxes of 5 tests, directly by pharmacies or under government contracts.

EBS 1005 includes 5 unit test kits, each including an instructions leaflet, a nasal swab to be inserted for only 2 to 3 centimeters into the nose, a ready-to-use reagent, and the test plate. Very easy to use with a minimally invasive sampling, the test gives a result in 10 minutes, with excellent performance (specificity> 99%, sensitivity> 93%).

This test complements Eurobio Scientific’s COVID diagnostics offering, which includes:

  • PCR tests including the proprietary EBX range with, among others, a test for the detection and qualification of SARS-CoV-2 variants (EBX 046),
  • automated serological tests, and
  • another proprietary antigen test for healthcare professionals, EBS 1020.

Marketed in several European countries, EBS 1005 helps support government strategies for managing the COVID-19 pandemic in parallel with vaccination campaigns.

About Eurobio Scientific

Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 148 employees and three production units based in the Paris region, in Germany and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany and Utrecht in The Netherlands.

For more information, please visit : www.eurobio-scientific.com

The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.
Symbol: ALERS – ISIN Code: FR0013240934 – Reuters: ALERS.PA – Bloomberg: ALERS:FP

Contacts

 

Group Eurobio Scientific
Denis Fortier, General Manager
Hervé Duchesne de Lamotte, General Manager
Tel. +33(0) 1 69 79 64 80
Calyptus
Mathieu Calleux / Gregory Bosson
Investors relations
Tel. +33(1) 53 65 68 68 [email protected]

 

Attachment

error: Content is protected !!